News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine

Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk.

News: Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments - CRISPR Medicine Eli Lilly to Acquire Verve Therapeutics to Advance One-Time Cardiovascular Treatments Eli Lilly announced today that it will acquire Verve Therapeutics for up to $1.3 billion to develop single-dose base-editing treatments for people with high cardiovascular risk. By: Karen O'Hanlon Cohrt - Jun. 17, 2025 Eli Lilly and Verve Therapeutics announced today that Lilly will acquire Verve for up to $1.3 billion. Under the terms of the agreement, Lilly will commence a tender offer to acqui

related reading

• NewLimit raises $435M led by Founders Fund to bring longevity medicines to human trialsblog.newlimit.com
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• Alphabet's Verily raises $1 billion as tech giants enter red hot healthcare sector | TechCrunchtechcrunch.com
• Curie.Biocurie.bio
• FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease | Scientific Americanscientificamerican.com
• List of Biotechnology Companies to Watch – AI Expanded Versionsubstack.com
• Medicine's Endgamenotboring.co
• The 23andMe Deal - Cremieux Recueilcremieux.xyz
• Treeline | Blogtreeline.bio
• Curious cases of financial engineering in biotechowlposting.com
• Gene Genies: Inside The Revolutionary Biotech That Can Edit DNA Inside Living Humansforbes.com
• Announcing Preventive — Preventivepreventive.bio